ALLO Straddle Strategy

ALLO (Allogene Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates.

ALLO (Allogene Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $568.2M, a beta of 0.46 versus the broader market, a 52-week range of 0.94-4.46, average daily share volume of 9.6M, a public-listing history dating back to 2018, approximately 226 full-time employees. These structural characteristics shape how ALLO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.46 indicates ALLO has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a straddle on ALLO?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

Current ALLO snapshot

As of May 15, 2026, spot at $2.00, ATM IV 49.20%, IV rank 6.72%, expected move 14.11%. The straddle on ALLO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this straddle structure on ALLO specifically: ALLO IV at 49.20% is on the cheap side of its 1-year range, which favors premium-buying structures like a ALLO straddle, with a market-implied 1-standard-deviation move of approximately 14.11% (roughly $0.28 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ALLO expiries trade a higher absolute premium for lower per-day decay. Position sizing on ALLO should anchor to the underlying notional of $2.00 per share and to the trader's directional view on ALLO stock.

ALLO straddle setup

The ALLO straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ALLO near $2.00, the first option leg uses a $2.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ALLO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ALLO shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$2.00	N/A
Buy 1	Put	$2.00	N/A

ALLO straddle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

ALLO straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on ALLO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use straddle on ALLO

Straddles on ALLO are pure-volatility plays that profit from large moves in either direction; traders typically buy ALLO straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

ALLO thesis for this straddle

The market-implied 1-standard-deviation range for ALLO extends from approximately $1.72 on the downside to $2.28 on the upside. A ALLO long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ALLO IV rank near 6.72% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ALLO at 49.20%. As a Healthcare name, ALLO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ALLO-specific events.

ALLO straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ALLO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ALLO alongside the broader basket even when ALLO-specific fundamentals are unchanged. Always rebuild the position from current ALLO chain quotes before placing a trade.

Frequently asked questions

What is a straddle on ALLO?: A straddle on ALLO is the straddle strategy applied to ALLO (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ALLO stock trading near $2.00, the strikes shown on this page are snapped to the nearest listed ALLO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are ALLO straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ALLO straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 49.20%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a ALLO straddle?: The breakeven for the ALLO straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ALLO market-implied 1-standard-deviation expected move is approximately 14.11%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on ALLO?: Straddles on ALLO are pure-volatility plays that profit from large moves in either direction; traders typically buy ALLO straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current ALLO implied volatility affect this straddle?: ALLO ATM IV is at 49.20% with IV rank near 6.72%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.